Cannell & Spears’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
Other funds holding AZN
Cannell & Spears's AZN Position: Q3 2026 in Review
Cannell & Spears reduced its AstraZeneca (AZN) stake by 0.18% in Q3 2026, selling an estimated $500 and leaving 1,663 shares worth $269K. The position accounts for ﹤0.01% of the portfolio, ranked #378.
Cannell & Spears first reported a position in AZN in Q1 2015 and has held it in 19 quarters since. The position peaked at $329K in Q1 2026. 1,446 funds tracked by Wall St. Rank hold AZN as of Q3 2026.
- Cannell & Spears held 1,663 shares of AstraZeneca worth $269K as of Q3 2026.
- Cannell & Spears sold 3 AstraZeneca shares in Q3 2026, an estimated $500.
- AstraZeneca made up ﹤0.01% of Cannell & Spears's portfolio in Q3 2026, its #378 holding.
- Cannell & Spears first reported a position in AstraZeneca in Q1 2015 and has held it in 19 quarters since.
- Cannell & Spears's AstraZeneca position peaked at $329K in Q1 2026.
- 1,446 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.
Based on Cannell & Spears's 13F filing for Q3 2026, filed 12 Nov 2026.